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Abstract
Purpose: A study was performed comparing dosimetric characteristics of volumetric modulated
arcs (RapidArc, RA) and fixed field intensity modulated therapy (IMRT) on patients with bilateral
breast carcinoma.
Materials and methods: Plans for IMRT and RA, were optimised for 10 patients prescribing 50
Gy to the breast (PTVII, 2.0 Gy/fraction) and 60 Gy to the tumour bed (PTVI, 2.4 Gy/fraction).
Objectives were: for PTVs V90%>95%, Dmax<107%; Mean lung dose MLD<15 Gy, V20 Gy<22%; heart
involvement was to be minimised. The MU and delivery time measured treatment efficiency. Pre-
treatment dosimetry was performed using EPID and a 2D-array based methods.
Results: For PTVII minus PTVI, V90% was 97.8 ± 3.4% for RA and 94.0 ± 3.5% for IMRT (findings
are reported as mean ± 1 standard deviation); D5%-D95% (homogeneity) was 7.3 ± 1.4 Gy (RA) and
11.0 ± 1.1 Gy (IMRT). Conformity index (V95%/VPTVII) was 1.10 ± 0.06 (RA) and 1.14 ± 0.09 (IMRT).
MLD was <9.5 Gy for all cases on each lung, V20 Gy was 9.7 ± 1.3% (RA) and 12.8 ± 2.5% (IMRT)
on left lung, similar for right lung. Mean dose to heart was 6.0 ± 2.7 Gy (RA) and 7.4 ± 2.5 Gy
(IMRT). MU resulted in 796 ± 121 (RA) and 1398 ± 301 (IMRT); the average measured treatment
time was 3.0 ± 0.1 minutes (RA) and 11.5 ± 2.0 (IMRT). From pre-treatment dosimetry, % of field
area with γ <1 resulted 98.8 ± 1.3% and 99.1 ± 1.5% for RA and IMRT respectively with EPID and
99.1 ± 1.8% and 99.5 ± 1.3% with 2D-array (ΔD = 3% and DTA = 3 mm).
Conclusion: RapidArc showed dosimetric improvements with respect to IMRT, delivery
parameters confirmed its logistical advantages, pre-treatment dosimetry proved its reliability.
Background
The aim of the present study was to investigate the poten-
tial clinical role of RapidArc, Varian Medical Systems
(Palo Alto, CA), for a particularly complex and rare case of
patients with synchronous bilateral breast carcinoma. In
this study, RapidArc delivery is compared with ''conven-
tional" fixed beam IMRT.
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Radiation Oncology 2009, 4:27 http://www.ro-journal.com/content/4/1/27RapidArc falls into the general category of volumetric
intensity modulated arc therapy (VMAT) [1-3] and it is a
planning and delivery technique based on an investiga-
tion from K. Otto [4]. RapidArc and its precursor have
been investigated previously for some other clinical cases
[5-11], showing significant dosimetric improvements
against other advanced techniques.
Breast radiation treatment with advanced techniques was
investigated previously by our group and results [12,13]
showed that in selected cases, IMRT is definitely beneficial
compared to conventional conformal approaches.
The simultaneous integrated boost (SIB) fractionation
strategy proposed in this study is justified by two rather
general objectives: i) reduce the length of treatment to
improve patient satisfaction and clinical throughput; ii) to
assess dosimetric potentials of advanced techniques and
planning capabilities.
Limited investigations on SIB in breast and on bilateral
breast irradiation are available in literature. Hurkmans et
al, Singla et al. and van der Laan et al. [14-16] analysed
this option proposing different schemes: 28x(1.81+2.3)
Gy or 31x(1.66+ 2.38) Gy for remaining breast and
tumour bed targets. In all cases, the SIB plans with IMRT
proved superior quality compared to sequential treat-
ments and authors [15] proposed to consider SIB as stand-
ard treatment. In the present study it was opted to propose
a further acceleration in the fractionation planning for 25
fractions (to keep treatment time limited to five weeks) of
2.0 Gy to entire breast with a simultaneous integrated
boost of 2.4 to the tumour bed. This fractionation has yet
to be proven to be clinically acceptable; however, it does
not impact the significance of comparative results.
Jobsen et al, Skowronek et al. and Yamauchi et al [17-19]
investigated the radiation therapy options as well as the
prognostic and incidence of synchronous or meta-
chronous bilateral breast cancer. These studies demon-
strated the technical feasibility of bilateral irradiation with
conventional techniques. The incidence of synchronous
bilateral breast cancer is quite low of the order of 1.5%
(18 patients over 1705 in the Jobsen study) associated to
a higher incidence of distant metastases and a worse dis-
ease free survival.
Although rare, synchronous bilateral breast irradiation is
a complex situation where the concomitant involvement
of both lungs and heart and the huge treated volume is a
particular challenge.
To minimise patient discomfort, it is advisable to investi-
gate also potentials of fast delivery techniques. While
standard treatment times are of the order of 15 minutes,
individual patient compliance with immobilisation
devices during 20–25 minute treatments may be compro-
mised because of their disease status or because of invol-
untary factors (e.g. coughing induced by swallowing in
the supine position). The drawback of some IMRT tech-
niques, is the extended time needed to deliver one frac-
tion, mostly because of the usage of multiple fields and
high number of MUs.
Purpose of the present investigation was: i) to assess, for a
relatively rare pathology, the quality of two advanced
treatment techniques in terms of expected dose distribu-
tions and pre-treatment dosimetric verification; ii) to
quantify the differences between the two solutions and
iii) to appraise logistic aspects as treatment efficiency. The
latter point does not necessarily apply to rare pathologies
but is of interest since, for RapidArc, multiple arcs were
applied instead of single arcs and knowledge of the
impact of arc multiplicity on treatment efficiency is still
limited.
Methods and patients
Patient selection and planning objectives
Anonymized CT data for a cohort of ten consecutive
patients treated for bilateral breast carcinoma after breast
conserving surgery, were used for the study. All patients
had ductal or lobular carcinoma in different quadrants,
stage T1(b or c), N0M0 and underwent breast conserving
surgery (lumpectomy); median age 69 (range: 67–85). CT
scans were acquired with 5 mm adjacent slice thickness in
free breathing mode. Scan extension included the entire
lung volume and reached, cranially, the supra-clavicular
level. In terms of lung volumes and relative positions of
lungs, heart and target volumes, free breathing can be con-
sidered as a first order surrogate of a mid-ventilation
phase of the breathing cycle. Treatment was planned with
patients in the supine position. The main organs at risk
(OAR) considered were lungs and heart. Lung mean vol-
umes were: 1080 ± 165 cm3 (left) 1390 ± 267 cm3 (right);
heart mean volume was: 377 ± 110 cm3. The healthy tis-
sue was defined as the patient's volume covered by the CT
scan minus the envelope of the various planning target
volumes (PTV).
Four target volumes were defined by radiation oncolo-
gists: CTVII (left and right) was the clinical target volume
encompassing the entire breast while CTVI (left and right)
was the boost volume defined by the tumour bed defined
as the lumpectomy volume. PTVII and PTVI (left and
right) were obtained with expansion of 8 mm in all direc-
tions except toward skin. PTVs were restricted to the skin
cropping at 5 mm from surface and to exclude the ribs.
The mean volumes were: PTVII: 612 ± 316 cm3 (left), 679
± 318 cm3 (right), PTVI: 47 ± 16 cm3 (left), 59 ± 29 cm3
(right). Target definition for CTVI was performed without
help of surgical clips, not implanted in the patients. This
procedure is acknowledged to be suboptimal and, in clin-Page 2 of 12
(page number not for citation purposes)
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improve this volume definition and to minimise risk of
geographical misses.
Dose prescription was according to a Simultaneous Inte-
grated Boost (SIB) scheme with 50 Gy (2 Gy/fraction) to
PTVII and 60 Gy (2.4 Gy/fraction) to PTVI. This fraction-
ation was assumed in absence of a general consensus in
literature on SIB strategy in breast as discussed in the
introduction. All plans were normalised to the mean dose
of the total PTVII minus PTVI (PTVII-PTVI) volume (i.e.
left plus right) as common practice for intensity modu-
lated plans and in agreement to forthcoming ICRU rec-
ommendations.
For all PTVs, plans aimed to achieve at least 95% of the
PTV receiving more than 90% of the prescribed dose and,
for PTVI, a maximum lower than 107% while keeping the
mean dose of each PTV as close as possible to the corre-
sponding prescription. Given the PTV definitions and
given the decision to avoid usage of bolus in this theoret-
ical study (in principle applicable to both IMRT and Rap-
idArc), the objectives on PTVII minimum dose are
expected to be difficult to respect. To prevent skin toxicity,
bolus usage should be minimised or, at least, applied on
alternate days and was considered as a potential con-
founding factor in the study. For lungs, given the bilateral
involvement, although conventional objectives were con-
sidered as acceptable (i.e. mean lung dose MLD<15 Gy
and volume receiving at least 20 Gy V20 Gy<22% [20-22]),
plans were designed to maximise lung sparing. Similarly
for heart, the planning strategy was to minimise mean and
maximum doses.
Planning techniques
Two sets of plans were compared in this study, all
designed by the same planner on the Varian Eclipse treat-
ment planning system (TPS) (version 8.6.10) with 6 MV
photon beams from a Varian Clinac equipped with a Mil-
lennium Multileaf Collimator (MLC) with 120 leaves
(spatial resolution of 5 mm at isocentre for the central 20
cm and of 10 mm in the outer 2 × 10 cm, a maximum leaf
speed of 2.5 cm/s and a leaf transmission of 1.8%). Plans
for RapidArc were optimised selecting a maximum DR of
600 MU/min and a fixed DR of 600 MU/min was selected
for IMRT.
The Anisotropic Analytical Algorithm (AAA) photon dose
calculation algorithm was used for all cases [23,24]. The
dose calculation grid was set to 2.5 mm.
IMRT
The dynamic sliding window method with fixed gantry
beams was used [25,26].
Plans were optimised for a mono-isocentric approach
with the single isocentre located medially under the ster-
num. Twelve beams with fixed jaws settings were applied,
starting from 120° and equally-spaced every 20° (exclud-
ing the 0° entrance). 6 beams were shaped to cover prima-
rily the left breast (120°, 100°, 80°, 340°, 320°, 300°)
and 6 the right breast (60°, 40°, 20°, 280°, 260°, 240°)
according to the pattern shown in figure 1. Beam angles
were selected in order to i) remain within the limit of 5–7
beams per target as described in [12]; ii) avoid posterior
entrance to enhance preservation of lungs and heart; iii)
mimic a sort of tangential distribution of beams. All
beams were coplanar with collimator angle set to 0° as per
institutional standards and because on fixed gantry flu-
ence based IMRT this has a marginal impact on modula-
tion capability. No bolus and no fluence expansion
outside body (skin flash) were applied to IMRT (and to
RapidArc). A high smoothing factor was applied during
optimisation (with the same priority of the highest prior-
ity used for dose volume objectives) to minimise the MU/
Gy from IMRT. The beam arrangement chosen for this
study resulted, among other investigated for the purpose,
the best trade-off between target coverage, OARs sparing
and practical feasibility. It is possible that other arrange-
ments could generate better plans but were not identified
for this study.
RapidArc (RA)
RapidArc uses continuous variation of the instantaneous
dose rate (DR), MLC leaf positions and gantry rotational
speed to optimise the dose distribution. Details about
RapidArc optimisation process have been published else-
where and readers are referred to original publications for
details [5,6]. To minimise the contribution of tongue and
groove effect during the arc rotation and to benefit from
leaves trajectories non-coplanar with respect to patient's
Beam arrangements, isocentre position and targets localiza-tion for IMRT and RapidArcFigure 1
Beam arrangements, isocentre position and targets 
localization for IMRT and RapidArc. For RapidArc, two 
arcs, rotating in opposite directions, are delivered in 
sequence, each arc aiming to geometrically cover primarily 
either left (red arc) or right targets (blue arc). For IMRT a 
similar approach was followed. Six fixed gantry field aimed to 
geometrically cover left targets (red lines showing the central 
beam axes) and the other 6 (blue lines) the right targets.Page 3 of 12
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a value different from zero [27]. In the present study col-
limator was rotated to ~10°–30° depending on the
patient. Plans were optimised with two arcs of 360° each.
The first arc, rotating clockwise, was incident primarily on
the right breast, the second arc, rotating counter-clock-
wise, was incident on the left breast as depicted in figure 1.
The same isocentre was used for IMRT and RapidArc
plans. In both cases, all fields or arcs were simultaneously
optimised to generate the desired dose distributions on all
targets.
Both RapidArc and IMRT plans were optimised using
exactly the same dose volume objectives and constraints
and with the same prioritisation of organs. Lung sparing
had higher priority than heart or normal tissue.
Pre-treatment Quality Assurance dosimetric 
measurements
To assess delivery quality and the agreement between cal-
culations and treatment, standardised pre-treatment qual-
ity assurance dosimetric measurements were performed
verifying each individual field or arc. Two dosimetry
methods and detectors were applied:
a) the GLAaS method. This method has been investi-
gated widely [28,29]. In brief, it consists in measure-
ments performed with the amorphous silicon portal
imager Portal Vision PV-aS1000, attached to the treat-
ment linac, with a calibration and processing method
converting raw data into absorbed doses at depth of
maximum (1.5 cm in this case). GLAaS has been
already tested for RapidArc delivery [28] and is the ref-
erence dosimetry tool in our centre for pre-treatment
verifications. With GLAaS no additional phantom has
to be used and, for RapidArc, the detector rotates
together with the gantry generating a sort of collapsed
or composite planar dose distribution. Spatial resolu-
tion of the GLAaS measurements is 0.392 mm in x and
y (PV-aS1000 pixel size).
b) The PTW-729 method. The 2D ion chamber array
from PTW (the 729 model) was used. For IMRT verifi-
cations the detector was positioned at isocentre with
an additional build up of 7 mm equivalent solid water
(to reach an equivalent measuring depth of 1.5 cm).
For RapidArc verification, the Octavius phantom
developed by PTW for rotational therapy verification
was used. In this case, the detector remains fixed on
the treatment couch during delivery and therefore the
measurement generates a planar dose different from
the GLAaS one but similarly of composite nature. To
compare measurements and calculations, the
Octavius-729 system was CT scanned and the Rapi-
dArc plans were recalculated on this CT dataset. Detec-
tor was positioned at isocentre. Spatial resolution of
PTW-729 measurements is coarser than with the
GLAaS being the detector made by square ion cham-
bers with 5 × 5 mm2 surface and inter-centre spacing
of 10 mm.
Evaluation tools
Evaluation of plans was based on Dose-Volume Histo-
gram (DVH) analysis. For PTV, the values of D98% and D2%
(dose received by the 98, and 2% of the volume) were
defined as metrics for minimum and maximum doses.
Also V90% V95% V107% and V110% (the volumes receiving at
least 90%, 95%, 107% or 110% of the prescribed dose)
were reported. The homogeneity of the dose distribution,
was measured by D5%-D95%. The lower this value, the bet-
ter is the dose homogeneity. Equivalent Uniform Dose
(EUD) was computed with α = 0.15 Gy-1, α/β = 2.8 Gy
[30].
Conformity Index, CI90% and CI95%, ratio between the
patient volume receiving at least 90% (95%) of the pre-
scribed dose and the volume of the total PTVII, measured
the conformity of the dose distribution. To account for the
spillage of prescription dose in the healthy tissue, the
External Volume Index (EI) was defined as VD/VPTVII where
VPTVII is the volume of the total PTVII and VD is the volume
of healthy tissue receiving more than 50 Gy.
For OARs, the analysis included the mean dose, the max-
imum dose expressed as D2% and a set of VXGy (OAR vol-
ume receiving at least × Gy) depending upon the organ.
Normal Tissue Complication Probability (NTCP) was
computed using the relative seriality model of Källmann
et al. [31,32]. The following values for the model's param-
eters were used: γ = 1.7, s = 0.03, D50 = 26.0 Gy for pneu-
monitis and γ = 3.0, s = 0.2, D50 = 49.0 Gy for pericarditis,
where s represents the degree of seriality for the organ, γ is
the dose-response steepness index and D50 is the dose to
the whole organ to induce NTCP = 50%.
For Healthy Tissue, the integral dose, "DoseInt" was
defined as the integral of the absorbed dose extended to
over all voxels excluding those within the target volume
(DoseInt dimensions are Gy*cm3). This was reported
together with the observed mean dose, V3 Gy and V10 Gy.
Average cumulative DVH for PTV, OARs and healthy tis-
sue, were built from the individual DVHs for qualitative
visualisation of results. These histograms were obtained
by averaging the corresponding volumes over the whole
patient's cohort for each dose bin of 0.05 Gy.
Delivery parameters were recorded in terms of MU per
fraction, mean dose rate, MU/degree, beam on time and
treatment time (defined as beam-on plus machine pro-Page 4 of 12
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tioning and imaging procedures).
Pre-treatment quality assurance results were summarised
in terms of the Gamma Agreement Index, GAI, scoring the
percentage of modulated area fulfilling the γ index criteria
[33] (computed with 2 and 3% and 2 and 3 mm thresh-
olds). The software utilised to analyse dosimetric data
were either the GLAaS package developed by authors or
the Verisoft (version 4.0) from PTW. In both cases, γ com-
putation was performed using the maximum dose value
in the calculated matrix as normalisation for dose differ-
ence evaluation. In both cases, γ was computed with
respect to the measured points and therefore was based on
a maximum of 729 entries in the PTW case and on a max-
imum of 1024 × 768 pixels in the GLAaS case (both
reduced according to the modulated field area seen by the
detector). Pre-treatment dosimetry was considered satis-
factory if GAI exceeded 95%.
The Wilcoxon matched-paired signed-rank test was used
to compare the results. The threshold for statistical signif-
icance was p = 0.05. All statistical tests were two-sided.
Results
Dose distributions are shown for one example in Figure 2
for axial views and three dose cuts (45 Gy, 90% of PTVII
prescription; 54 Gy, 90% of PTVI prescription, and 10
Gy). Figures 3 and 4 show the average DVH for all the
PTVs, lungs, heart and healthy tissue. Tables 1, 2 and 3
summarise numerical findings from DVH, delivery and
pre-treatment dosimetry analyses. Data are presented as
averages over the investigated patients and errors indi-
cated inter-patient variability at 1 standard deviation
level.
Figure 5 shows the results from pre-treatment quality
assurance for one IMRT field and one RapidArc arc from
the two dosimetric methods applied in the study. Shown
are the planar dose maps at isocentre (2D-array) and 1.5
cm depth (GLAaS) computed from the measured data, the
2D γ map from the comparison against corresponding cal-
culations and a profile along the y direction. Summary of
numerical findings is reported in table 3 together with the
results from other delivery parameters.
Target coverage and dose homogeneity
Data in the tables are reported for the total target volumes,
combining left and right sides, as well as for the separated
targets referring the DVH for each PTV to the dose pre-
scribed (e.g. for PTVI 100% = 60 Gy). In general, RapidArc
and IMRT achieved similar results. IMRT resulted in a
slight under dose to the boost volume while RapidArc bet-
ter respected the dose prescription. RapidArc reduced
D5%-D95% of more than 3.5 Gy to bilateral PTVII-PTVI
compared to IMRT. Similarly, homogeneity was improved
in the case of PTVI. A reduction of over dosages in the
PTVII-PTVI volume for RapidArc was also observed com-
pared to IMRT. RapidArc showed also an improvement in
target coverage: for PTVII-PTVI or PTVI (V90%). EUD
improved of ~1 Gy on PTVII-PTVI and PTVI for RapidArc
compared to IMRT.
Equivalent findings were obtained analysing each target
separately, proving no differences in the optimisation of
dose distributions between the right or left sides of the
patient.
Organs at risk
High sparing of lungs was achieved with both techniques.
The observed differences on MLD are not statistically sig-
nificant. At medium to high levels, RapidArc proved to be
slightly superior to IMRT. At low dose levels, e.g. V5 Gy,
IMRT was better than RapidArc.
For the heart, RapidArc results were superior to IMRT at all
dose ranges.
Healthy tissue
The mean and the integral dose were found to be higher
with RA with respect to IMRT due to a higher contribution
at low dose levels (e.g. V3 Gy). On the contrary, RapidArc
Example of dose distributions on axial views for one caseFigure 2
Example of dose distributions on axial views for one 
case. Color wash thresholds were set to 45 or 54 Gy, 95% 
of the respective dose prescriptions to PTVII and PTVI, and 
to 10 Gy to represent the total dose bath.Page 5 of 12
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Mean DVHs (averaged over the 10 patients) for the various PTVsFigure 3
Mean DVHs (averaged over the 10 patients) for the various PTVs.
Radiation Oncology 2009, 4:27 http://www.ro-journal.com/content/4/1/27was better than IMRT in lowering the high dose levels for
soft tissues of interest (e.g., to improve cosmetic results).
RapidArc reduced EI compared to IMRT.
Delivery parameters
The ratio between number of MU per fraction of 2 Gy (2.4
Gy on the boost volumes) resulted to be MUIMRT/MURA =
1.76. The average dose rate for RA deliveries resulted
~60% of the fixed dose rate applied to IMRT deliveries
and, upfront to a statistically not significant difference in
beam on time, the treatment time was nearly 74% less for
RapidArc compared to IMRT. This is mostly due to the
need to reprogram the linac between fixed gantry beams,
rotate the gantry from one position to the next and to
deliver split fields (since with dynamic sliding window
IMRT, main jaws are fixed during delivery, fields exceed-
ing ~14 cm in width are split in two or three carriage
groups to compensate for this hardware feature; in the
present study, in average three-four beams per patients
were split). For RapidArc, all individual arcs could be
delivered between 83 to 85 seconds of beam on time.
Pre-treatment dosimetric measurements
A summary of findings is reported in table 3 for the vari-
ous combinations of thresholds. Concerning GLAaS, the
dosimetric agreement between calculation and delivery
resulted to be highly satisfactory. Similarly high quality
results were obtained with the PTW-729 system.
Discussion and conclusion
The planning case selected for this investigation is highly
demanding because of several factors: i) total target vol-
umes are huge (about 1400 cm3), ii) bilateral involve-
ment of lungs and of heart requires tight avoidance
capabilities, iii) treatment shall be technically easy to
administer and as fast as possible.
Mean DVHs (averaged over the 10 patients) of the left and right lungs, heart and healthy tissue (total body volume in the CT set minus the total PTVII)Figure 4
Mean DVHs (averaged over the 10 patients) of the left and right lungs, heart and healthy tissue (total body vol-
ume in the CT set minus the total PTVII).Page 7 of 12
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treatment plans of high quality with one single isocentre
located in the mid-line of the sternum to allow easy and
safe management of patients. This was achieved nicely by
both techniques but required the application of 12 beams
with IMRT and 2 independent arcs with RapidArc. Con-
cerning RapidArc, due to their simultaneous optimisa-
tion, each of the two arcs contributes to the dose at both
sides even though each is geometrically mainly incident
on either the left or right target only. Some under-dosage
of PTVs was expected and due to the extension of the tar-
gets till the proximity of patient's surface. To eliminate
this feature it would be possible to further crop PTV inside
the body [14] or to add a bolus in the optimisation and
calculation phases. Both approaches were not followed to
stick with institutional standards and to generate plans
under the most restrictive conditions. Nevertheless Rapi-
dArc respected the planning objective on V90% while IMRT
presented a minor violation. Concerning IMRT plans, the
decision to avoid bolus in the optimisation does not
increase the risk of excessive skin toxicity because in
Eclipse fluence matrices are normally generated without
un-necessarily high fluence in those beamlets impinging
tangentially to the skin to compensate for low doses in the
build-up region. In addition, the usage of high smoothing
factors further reduces the presence of small hot (or cold)
spots in the fluence matrices as well as reduces high fre-
quency changes in the intensity of the fluence beamlets.
The quality of delivered doses compared to the computed
was assessed with pre-treatment dosimetry. RapidArc and
IMRT proved to be equivalent using two totally independ-
ent methods of verification. The excellent quality of dosi-
metric results guarantees about the safety of the newer
technique. Sensitivity of the RapidArc technique to tighter
thresholds was investigated and proved to be highly satis-
factory with both the GLAaS and PTW-729 methods. The
quality of GLAaS based measurement for RapidArc is con-
firmed in other studies with different detectors [10,34]
where either gafchromic films or other 2D systems were
Table 1: Summary of DVH based analysis for the PTVII and PTVI
PTVII-PTVI (left and right) PTVI (left and right)
RapidArc IMRT p RapidArc IMRT p
Mean (Gy) 50 50 - 59.6 ± 0.9 58.0 ± 0.9 0.004
EUD (Gy) 48.5 ± 0.6 47.6 ± 0.8 0.003 58.9 ± 0.7 57.7 ± 1.0 0.004
D5%-D95%(Gy) 7.3 ± 1.4 11.0 ± 1.1 0.004 3.4 ± 0.7 5.8 ± 0.9 0.50
D2%(Gy) 55.8 ± 1.1 57.2 ± 1.6 0.004 62.3 ± 0.8 61.9 ± 1.4 0.145
D98%(Gy) 45.1 ± 1.2 43.4 ± 1.3 0.004 55.8 ± 1.3 54.1 ± 1.3 0.035
V90%(%) 97.8 ± 2.4 94.0 ± 3.5 0.004 99.3 ± 1.5 97.5 ± 3.0 0.035
V107%(%) 8.3 ± 5.1 14.0 ± 5.3 0.004 0.0 ± 0.0 0.0 ± 0.0 0.004
V110%(%) 4.0 ± 2.3 8.5 ± 4.3 0.035 0.0 ± 0.0 0.0 ± 0.0 -
PTVII left PTVII right
RapidArc IMRT p RapidArc IMRT p
Mean (Gy) 51.0 ± 0.3 50.8 ± 0.3 0.004 50.9 ± 0.8 50.5 ± 0.6 0.145
EUD (Gy) 48.8 ± 0.7 47.7 ± 0.9 0.002 48.7 ± 0.6 48.0 ± 0.7 0.06
D5%-D95%(Gy) 9.7 ± 0.9 14.2 ± 1.4 0.363 9.8 ± 1.8 10.5 ± 1.3 0.363
D2%(Gy) 60.6 ± 1.3 59.7 ± 1.4 0.363 60.2 ± 1.6 59.7 ± 1.7 0.145
D98%(Gy) 45.2 ± 1.5 43.6 ± 1.6 0.004 45.2 ± 1.3 43.5 ± 1.0 0.004
V90%(%) 98.0 ± 2.1 94.7 ± 3.4 0.004 95.7 ± 2.4 93.3 ± 2.4 0.004
V110%(%) 10.4 ± 2.6 14.2 ± 5.5 0.035 10.1 ± 5.2 13.4 ± 5.6 0.004
PTVI left PTVI right
RapidArc IMRT p RapidArc IMRT p
Mean (Gy) 59.4 ± 1.1 58.6 ± 1.4 0.06 59.7 ± 0.8 58.5 ± 0.6 0.004
EUD (Gy) 59.8 ± 0.5 58.3 ± 0.7 0.03 59.7 ± 0.9 57.4 ± 1.3 0.005
D5%-D95%(Gy) 5.8 ± 0.6 7.4 ± 1.0 0.5 4.3 ± 1.0 5.7 ± 1.5 0.145
D2%(Gy) 62.1 ± 1.2 60.3 ± 1.8 0.5 62.2 ± 0.6 62.2 ± 1.6 0.145
D98%(Gy) 55.7 ± 1.4 54.0 ± 1.2 0.004 56.0 ± 1.3 54.3 ± 1.3 0.035
V90%(%) 99.5 ± 0.6 98.5 ± 2.0 0.035 99.5 ± 0.8 97.9 ± 2.5 0.035
V110%(%) 0.0 ± 0.0 0.2 ± 0.5 0.5 0.0 ± 0.0 0.0 ± 0.0 -
Data are reported as mean ± 1 standard deviation computed over the cohort of 10 patients.
Dx% = dose received by the x% of the volume; Vx% = volume receiving at least x% of the prescribed dose; EUD = Equivalent Uniform Dose.
* p < 0.05; ** p < 0.01Page 8 of 12
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This consistency suggests also the limited relevance of the
fact that with GLAaS dosimetry the EPID detector rotates
together with the gantry although it would not allow
detecting potential mismatches between planned and
actual positions.
The second objective was to quantify quality of dose dis-
tributions and potential differences between RapidArc
and IMRT. The data shown here suggest that both tech-
niques are satisfactory. RapidArc offers some improve-
ment on target coverage, homogeneity and lung and heart
sparing. Concerning V5 Gy, as can be derived from the
graphs in figure 4, the steep gradient of DVHs in the low
dose range, makes the absolute validity of numbers ques-
tionable since small deviations in dose thresholds corre-
sponds to huge variations in volumes. The clinical
relevance of the observed differences cannot be drawn
simply from a planning study with limited statistical
power and appropriate trials should be performed.
The third objective was to assess treatment efficiency. Pure
beam on time was equivalent between IMRT and Rapi-
dArc. Total treatment time was assessed measuring the
time needed from loading the first beam to completing
the last beam, i.e. accounting for all technical delivery
aspects but excluding patient positioning and pre-treat-
ment imaging procedures to verify patient positioning
that should be equivalent between techniques. RapidArc
treatment times were 74% shorter than IMRT implying a
reduction of the risk of intra-fractional movements. The
number of split fields with single isocentre IMRT is not
higher than a corresponding value if double isocentre is
used, since the field width is dominated by the PTVII
width and field sizes are similar with both approaches
thanks to the usage of asymmetric jaws settings. The
present comparison refers anyway to a specific implemen-
tation of fixed beam IMRT, the Dynamic Sliding Window.
Different approaches, e.g. based on direct aperture, or
with fewer gantry angles or with few segments or avoiding
split fields, could improve efficiency of IMRT.
Table 2: Summary of DVH based analysis for OARs and healthy tissue
Left Lung Right Lung
RapidArc IMRT p RapidArc IMRT p
Mean (Gy) 8.7 ± 1.0 7.8 ± 0.9 0.15 9.4 ± 1.2 9.1 ± 1.4 0.4
D2%(Gy) 34.3 ± 2.3 39.4 ± 4.1 0.04 37.9 ± 1.7 44.8 ± 2.5 0.004
V5 Gy(%) 58.7 ± 18.9 35.3 ± 3.9 0.004 58.3 ± 18.9 44.4. ± 7.8 0.004
V20 Gy(%) 9.7 ± 1.3 12.8 ± 2.5 0.04 10.3 ± 1.4 14.5 ± 4.0 0.004
V45 Gy(%) 0.1 ± 0.2 0.9 ± 0.7 0.04 0.1 ± 0.1 0.9 ± 0.5 0.004
NTCP (%) <0.1 <0.1 0.3 <0.1 <0.1 0.2
Heart
RapidArc IMRT p
Mean (Gy) 6.0 ± 2.7 7.4 ± 2.5 0.14
D2%(Gy) 17.0 ± 6.6 24.4 ± 7.1 0.04
V10 Gy(%) 13.1 ± 14.1 19.5 ± 13.3 0.04
V45 Gy(%) 0.0 ± 0.0 0.1 ± 0.1 0.12
NTCP (%) <0.1 <0.1 0.25
Healthy Tissue
RapidArc IMRT p
Mean (Gy) 7.1 ± 0.3 5.0 ± 0.4 0.03
V3 Gy(%) 50.1 ± 8.7 33.5 ± 6.1 0.03
V10 Gy(%) 20.5 ± 3.3 18.3 ± 2.7 0.19
CI90 1.19 ± 0.07 1.20 ± 0.07 0.19
CI95 1.10 ± 0.06 1.14 ± 0.09 0.19
EI (%) 3.7 ± 1.9 8.7 ± 2.9 0.19
DoseInt (Gycm-3105) 1.40 ± 0.36 1.15 ± 0.27 0.03
Data are reported as mean ± 1 standard deviation computed over the cohort of 10 patients.
Dx% = dose received by the x% of the volume; VxGy = volume receiving at least × Gy; CI = ratio between the patient volume receiving at least 90% 
and 95% of the prescribed dose and the volume of the total PTVII; EI = VD/VPTVII where VPTVII is the volume of the total PTVII and VD is the volume 
of healthy tissue receiving more than 50 Gy; DoseInt = integral of the absorbed dose extended to over all voxels excluding those within the target 
volume; NTCP = Normal Tissue Control Probability with the relative seriality model.
* p < 0.05; ** p < 0.01Page 9 of 12
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agement and breath control. In the study and in clinical
practice for similar patients, no breast immobilisation sys-
tem is applied, but only an arm support is used. Immobi-
lisation could be advisable in the case of large breasts but,
at present, no satisfactory solution was found at our insti-
tute. From the dosimetric point of view, avoidance of
lungs and of heart in breast irradiation was proven to be
significantly improved [35] if irradiation is performed
with gated delivery in the deep inspiration phase. At the
current stage, breath control is available for conventional
IMRT but not yet for RapidArc. Nevertheless, the mid-ven-
tilation phase could be an adequate surrogate of breath
control since, statistically, it is the phase where targets can
be ''seen" by static beams for the longest time provided
adequate margins are defined. In the present study, the CT
dataset used can be considered as average mid-ventilation
phase partially solving the issue. A recent investigation
[36] proved the principle feasibility of target tracking in
combination with RapidArc delivery. In absence of
advanced methods, mid-ventilation could be applied as a
first degree approach. Concerning management of (resid-
ual) breast movements mainly due to respiration, skin
flash tools, aiming to expand beam fluence outside the
body outline, have been proven and are normally used for
IMRT treatments. In this study, no skin flash was applied,
as mentioned in the methods, for two reasons: i) at plan-
ning level, the application of skin flash outside body out-
line has a minimal impact on the dose distribution since
no dose is computed outside the body outline; ii) Rapi-
dArc, being based on different optimisation processes,
does not generate a fluence map that can be ''expanded"
outside the body to compensate for any effect. It is never-
theless obvious that, for treatment of real patients, it
would be advisable to use both gated delivery and skin
flash when normal IMRT is applied. For RapidArc, a work-
around, to mimic skin flash, consists in the following
process: i) generate two 3D CT dataset, one for dose calcu-
lation and one for plan optimisation; ii) expand the body
in the optimisation CT dataset to artificially ''enlarge" the
body outline, draw an enlarged target structure extending
outside the original body outline, and perform optimisa-
tion on those wider body and target; iii) perform final
dose calculation on the original CT dataset to account for
the real size of the patient. This procedure has been tested
for other patients and results technically feasible and
could be considered as a first order, manual, substitute of
the skin flash tool in RapidArc.
RapidArc was investigated for synchronous bilateral
breast cancer and compared to fixed beam IMRT. Rapi-
dArc produced plans of high quality. Pre-treatment qual-
ity assurance showed reliability and high degree of
agreement between calculated and delivered doses for
both IMRT and RapidArc. RapidArc reduced treatment
time of ~74%. The potential benefit of a better physical
dose distribution, combined with a shorter delivery time
makes RapidArc of interest also in the breast case, particu-
larly in the perspective of target tracking.
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Table 3: Summary of delivery parameters and pre-treatment dosimetric tests
Delivery parameters
2 Gy/fraction RapidArc IMRT
Monitor Units (MU) 796 ± 121 1398 ± 301 p < 0.01
MeanDose Rate (MU/min) 378 ± 46 600 fixed -
Mean MU/° 1.1 ± 0.2 - -
Beam on time (min) 2.30 ± 0.01 2.23 ± 0.40 p = 0.14
Treatment time (min) 3.00 ± 0.08 11.45 ± 2.05 p < 0.01
Pre-treatment Quality Assurance
RapidArc IMRT
GLAaS PTW729 GLAaS PTW729
GAI (3% 3 mm) (%) 98.8 ± 1.3 a 98.8 ± 1.3 a 99.1 ± 1.5 a 99.5 ± 1.3 a
GAI (2% 3 mm) (%) 97.0 ± 2.8 a 97.0 ± 2.8 a 97.2 ± 4.3 a 98.4 ± 3.0 a
GAI (2% 2 mm) (%) 93.0 ± 5.0 93.0 ± 5.0 94.4 ± 4.3 96.3 ± 4.3
Data are reported as mean ± 1 standard deviation computed over the cohort of 10 patients.
GAI is the Gamma Agreement Index, percentage of field area of percentage of measured points fulfilling the criteria γ <1.
* p < 0.05; ** p < 0.01; a p < 0.05 w.r.t. GAI = 95%Page 10 of 12
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Example of pre-treatment dosimetric measurements with the GLAaS method and with the PTW-729: a) IMRT, b) RapidArcFigure 5
Example of pre-treatment dosimetric measurements with the GLAaS method and with the PTW-729: a) 
IMRT, b) RapidArc. In each figure it is shown: i) 2D dose maps calculated by Eclipse and measured at Linac. Planes shown are 
at 15 mm depth in water (GLAaS) or at isocentre PTW-729); ii) the 2D γ map for GLAaS or the overlay between the calcu-
lated 2D dose map and the detector points violating the threshold γ <1; iii) dose profiles along the dashed line shown in the 2D 
maps, comparing measure and calculation. In the case PTW-729 calculation is the solid line while measurements are the points.
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